PrEP for HIV: effectiveness, how to take it, side effects, testing and cost

PrEP in brief: what it is and what it is not

PrEP stands for pre-exposure prophylaxis. It means taking specific HIV medicines before possible risk situations so HIV cannot establish itself. The WHO has recognised PrEP for years as an important part of HIV prevention. WHO: Pre-exposure prophylaxis

The distinction matters: PrEP protects against HIV, but not against chlamydia, gonorrhoea, syphilis or other sexually transmitted infections. If you are generally unsure how to interpret symptoms or risk contacts, Do I have an STI? can help you sort that out.

Who may benefit from PrEP

PrEP is not an identity issue. It is a risk decision. It may be useful when there are repeated situations in which there is meaningful HIV risk and other protection strategies on their own are not dependable enough.

• anal or vaginal sex without reliable barrier protection
• recurrent sexual contact with partners whose HIV status or treatment situation is unclear
• frequent new partners or periods with many encounters
• sex work when protection cannot always be planned properly
• shared injecting equipment or other relevant risks linked to drug use
• repeated need for PEP after condom failures or similar situations

Modern guidelines take a pragmatic line here. PrEP should not be restricted more than necessary and should also be open to people who judge for themselves that they are likely to benefit from it. That matches the direction international care has taken.

How effective PrEP really is

The main question is usually how effective PrEP really is. The short answer is: very effective when used correctly. The CDC states that PrEP can reduce HIV risk from sex by about 99 per cent when it is taken as prescribed. CDC: PrEP

The decisive point is not a single percentage but adherence. PrEP does not protect automatically. It works when adequate drug levels are present at the right time. Anyone who repeatedly misses doses or chooses an unsuitable schedule loses protection.

Care data from Germany fit that picture as well. A five-year Hamburg cohort reported no HIV cases during active PrEP use, whilst bacterial STIs still remained common. That is a realistic reminder of what PrEP does very well and what it does not do. PubMed: Five-Year German PrEP cohort

Which forms of PrEP are available

In day-to-day practice, daily oral PrEP with tenofovir and emtricitabine remains the established standard. Internationally, some countries now also use other oral options or longer-acting approaches.

Daily oral PrEP

One tablet a day is the classic model. It is easiest to plan, best studied for most people, and the standard when risk is not only occasional or when different exposure types may matter.

Event-driven PrEP

So-called 2-1-1 or on-demand PrEP is not taken every day but around particular sexual encounters. It is much less forgiving than daily use, so it does not suit every person or every situation.

Other options internationally

Current guidelines outside Germany also mention other oral regimens and long-acting injection options. Whether any of those are actually available to you depends heavily on the country, approval status and coverage. For your own care, it is better to ask the service that would prescribe it than to rely on headlines.

2-1-1 PrEP: useful, but only in clearly limited scenarios

Precision matters here. Event-driven PrEP is not simply a lighter version of daily PrEP. It is only well established for certain people and certain exposure types.

The 2025 Canadian guideline clearly recommends 2-1-1 for cis men and trans women when HIV risk is linked to sex with cis men. For vaginal sex and for risks connected with injecting drugs, 2-1-1 is not a standard option. That is exactly why this choice belongs in medical counselling rather than self-experimentation.

If you need a plan that works in ordinary life without calculations and timing pressure, daily PrEP is often the more robust choice.

When PrEP starts working

The answer depends on the dosing mode and the type of exposure. The CDC cites about seven days to maximum protection for receptive anal sex with daily oral PrEP, and about 21 days for receptive vaginal sex and for risks linked to injecting drug use. CDC: Talk PrEP Together

For other constellations, the evidence is less direct. In practice, that means not relying on rules of thumb from forums. Start PrEP in a way that avoids a gap before full protection is in place. That is why PrEP should not be started at the very last moment before an expected risk situation.

Starting PrEP: which tests are needed first

PrEP should not be started casually or on guesswork. Before beginning, it needs to be clear that there is no existing HIV infection. Good official guidance repeats this point because PrEP is not treatment for established HIV. A clear overview is in the CDC clinical guidance. CDC HIV Nexus: Clinical Guidance for PrEP

• an HIV test before starting
• checking for symptoms of a possible acute HIV infection
• kidney function, depending on the regimen being considered
• hepatitis B status, because some PrEP medicines also act against hepatitis B
• testing for other STIs at the relevant body sites
• depending on the situation, a pregnancy test and other baseline blood tests

If you are under time pressure after a very recent risk event, PrEP is not automatically the right tool. When a possible exposure happened within the last 72 hours, the real issue is more likely PEP after a condom split or another risk situation.

How to get PrEP through local services

In practice, PrEP usually begins with counselling, HIV testing, baseline blood tests and a prescription from a qualified clinician or service. The details can vary, but the basic pathway is similar: assess risk, rule out HIV, choose the right regimen and organise follow-up.

If you are unsure where to begin, a sexual health clinic or GP can usually point you to the right service. In the UK, access routes and ongoing monitoring can differ between services, so checking locally before you start is still sensible.

Which follow-up checks belong with ongoing PrEP

PrEP is not about vaguely being checked now and then. It works best within a structured medical framework. In practical terms, that usually means HIV testing at set intervals, STI screening matched to risk and kidney monitoring for TDF-based PrEP.

The RKI FAQ and the German-Austrian guideline both emphasise that PrEP belongs in a structured care model with continuing follow-up. RKI: FAQ on HIV PrEPAWMF: S2k guideline on HIV PrEP

• regular HIV testing
• STI tests, often at several body sites rather than urine only
• kidney monitoring, especially for older adults or people with pre-existing conditions
• counselling about side effects, adherence and pauses

If you want more detail specifically on HIV testing strategy, HIV self-test, rapid test and lab test is a useful companion article.

PrEP side effects: what is realistic and what is mostly myth

The honest answer is neither minimising nor dramatic: most people tolerate oral PrEP well, especially after the first phase. Typical early issues are mild nausea, headaches or stomach upset in the first days or weeks.

Long term, the main concerns are less about day-to-day discomfort and more about two topics: kidneys and, with some regimens, bone metabolism. That is why follow-up appointments are not merely administrative. They are part of the safety plan.

The German cohort from Hamburg found overall stable kidney values under TDF and FTC. That does not mean follow-up is optional. It means PrEP is often manageable when the regimen is chosen properly and monitoring is organised well. PubMed: German PrEP cohort

Drug interactions, kidneys and hepatitis B

To many people, PrEP sounds like just one tablet. Medically, the picture is broader. Pre-existing conditions, other medicines and hepatitis B can all affect which option fits best. The CDC especially recommends paying attention to kidney function and hepatitis B status. CDC HIV Nexus: Clinical Guidance for PrEP

• medicines that may stress the kidneys should be discussed openly
• with chronic hepatitis B, both regimen choice and stopping PrEP need extra care
• if new symptoms or new medicines appear, it is better to check back than improvise

The most common practical mistake is not a rare interaction. It is that important information is never mentioned during the appointment.

PrEP without condoms: what is protected and what is not

Many people want a direct answer here: is sex without condoms safe if you are on PrEP? For HIV, PrEP can be highly protective when used correctly. For other STIs, it does not offer that protection. So PrEP is not a universal solution. It is a targeted HIV prevention strategy.

The German cohort shows that tension clearly: strong protection against HIV, but continuing STI burden. That is why topics such as chlamydia, gonorrhoea and syphilis still matter in routine PrEP care.

If condoms do not fit your actual life very well, PrEP can still be a very sensible step. The decision just needs to be honest: HIV protection, yes. STI protection, no.

PrEP in relationships and U=U

In committed relationships, PrEP is often not only about casual sex but also about serodifferent couples. A second prevention concept matters here: U=U. When a person living with HIV is on effective treatment and has a durably undetectable viral load, HIV is not sexually transmitted. HIV.gov: Viral suppression and U=U

PrEP can still have a role in these relationships, for example during the period before viral suppression is stable, when the treatment situation is uncertain, or simply as an additional layer of reassurance. Then the question is less about rigid right or wrong and more about an informed decision made together.

PrEP when trying to conceive, during pregnancy and while breastfeeding

This topic matters in counselling even if many summaries mention it only briefly. The CDC notes that oral PrEP with tenofovir and emtricitabine can also be an option during periods of trying to conceive, pregnancy and breastfeeding when meaningful HIV risk continues. CDC HIV Nexus: PrEP in pregnancy and breastfeeding

What matters here is not do-it-yourself research but choosing the right regimen and arranging follow-up through a clinician with experience in HIV prevention and pregnancy. In some situations PrEP is very sensible. In others, the partner's treatment situation or another protection strategy may already be enough.

PrEP costs: what may be covered

Costs can differ substantially depending on country, service model and whether medicines and follow-up testing are funded together. What matters is the indication, the prescribing pathway and how the monitoring programme is organised.

If you need clarity, ask early at the clinic or service that would prescribe PrEP, or check directly with the relevant funding route. In the UK, what is arranged locally can affect the practical details, so it is better to confirm that before starting.

Pausing PrEP, missed doses and restarting

Many people do not only want to know how to start. They also want to know what happens if they miss tablets, pause for a while or restart later. That is exactly where the most dangerous half-truths appear. Whether protection is still present or needs to be rebuilt depends on the regimen, the exposure type and the length of the interruption.

• do not switch back and forth between daily dosing and 2-1-1 on your own
• if several doses were missed, contact the prescribing service
• before a planned pause, clarify how protection tapers off
• after a longer break, do not assume full protection returns immediately

If there has already been a concrete exposure and PrEP was not taken correctly, the right next step may be urgent PEP assessment rather than simply carrying on.

Myths and facts about PrEP

• Myth: PrEP protects against all STIs. Fact: PrEP specifically protects against HIV, not against chlamydia, gonorrhoea, syphilis or other STIs.
• Myth: If you take PrEP, you no longer need testing. Fact: Testing and follow-up are a core part of safe PrEP use.
• Myth: 2-1-1 is simply a cheaper option for everyone. Fact: Event-driven PrEP is only well established for certain people and exposure types.
• Myth: PrEP automatically harms the kidneys. Fact: Most people tolerate PrEP well. Kidney checks are there to identify problems early if they arise.
• Myth: PrEP and PEP are the same thing. Fact: PrEP is taken before risk. PEP is an urgent intervention after possible exposure.
• Myth: Taking PrEP automatically means sex without condoms. Fact: PrEP does not replace a broader STI strategy. It adds focused HIV protection.

When to seek medical help quickly

Do not wait for the next routine appointment if you had a recent risk event, develop flu-like symptoms after possible HIV exposure, or had a clear dosing mistake plus a risk event whilst on PrEP.

• possible HIV exposure within 72 hours
• fever, rash, swollen lymph nodes or marked symptoms after a risk event
• new relevant kidney problems or abnormal blood results
• pregnancy or trying to conceive when prevention needs to be adjusted
• repeated STI diagnoses if the current prevention strategy no longer fits

Conclusion

PrEP is one of the most effective HIV prevention strategies available when the right dosing pattern is chosen, HIV is clearly ruled out before starting, and follow-up checks are taken seriously. What matters most are realistic selection, regular testing and an honest view of which risks PrEP covers and which it does not.